Teplizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CD3 |
| Clinical data | |
| Trade names | Tzield, others |
| Other names | teplizumab-mzwv, PRV-031, MGA031 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a622077 |
| License data |
|
| Routes of administration | Intravenous |
| Drug class | Antidiabetic agent |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6462H9938N1738O2022S46 |
| Molar mass | 145801.49 g·mol−1 |
Teplizumab, sold under the brand name Tzield among others, is an anti-CD3 humanized monoclonal antibody and the first approved treatment indicated to delay the onset of stage 3 type 1 diabetes in people living with stage 2 type 1 diabetes. Type 1 diabetes progresses from stage 1 (where a person has normal blood sugar but tests positive for two or more diabetes-related autoantibodies) to stage 2 (when blood sugar becomes abnormal, but they have no symptoms), to stage 3 (where significant beta cell loss has occurred and they typically have symptoms of type 1 diabetes); teplizumab delays the progression from stage 2 to stage 3.
Teplizumab's mechanism of action involves binding to CD3 protein complexes (a molecule involved in recognising antigens and activating T cells) on the surface of T-cells and modifying T-cell immune behaviour to reduce cytotoxicity. This appears to involve weak agonistic activity on signaling via the T cell receptor-CD3 complex associated with the development of anergy, unresponsiveness, and/or apoptosis, particularly of unwanted activated T effector cells. In addition, regulatory cytokines are released and regulatory T cells are expanded that may lead to the reestablishment of immune tolerance. To avoid overly stimulating cytokine release, the Fc region of this antibody has been engineered to have Fc receptor non-binding (FNB) properties.
Teplizumab was approved for medical use in the United States in November 2022, and in the European Union in January 2026. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.